Nicht lieferbar
Delivery of siRNA for Masking Resistance to Chemotherapy in Non-Small Cell Lung Cancer
Versandkostenfrei!
Nicht lieferbar
The development of resistance to chemotherapy is a major challenge in the treatment of non-small cell lung cancer (NSCLC), which is a leading cause of cancer-related mortality worldwide. RNA interference (RNAi) is a promising approach for addressing this challenge by selectively silencing genes responsible for drug resistance. One of the key components of RNAi is small interfering RNA (siRNA), which can specifically target and silence genes. The delivery of siRNA to cancer cells is a major challenge due to its instability and inefficient cellular uptake. Various strategies have been developed ...
The development of resistance to chemotherapy is a major challenge in the treatment of non-small cell lung cancer (NSCLC), which is a leading cause of cancer-related mortality worldwide. RNA interference (RNAi) is a promising approach for addressing this challenge by selectively silencing genes responsible for drug resistance. One of the key components of RNAi is small interfering RNA (siRNA), which can specifically target and silence genes. The delivery of siRNA to cancer cells is a major challenge due to its instability and inefficient cellular uptake. Various strategies have been developed to overcome these challenges, including the use of nanoparticles, liposomes, and other delivery vehicles. These strategies have shown promising results in preclinical studies and hold great potential for clinical translation. The development of effective siRNA delivery systems for masking resistance to chemotherapy in NSCLC can potentially improve the efficacy of chemotherapy and enhance patient outcomes.